26.35
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eurobio Scientific
Its shares trade on Euronext Paris under the ticker ALERS.PA. It has been listed since 18 November 2005. In the fiscal year to 31 December 2025, it reported revenue of €169.0m and net income of €4.9m. At that date it held total assets of €256.8m and shareholders' equity of €183.9m.
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Nov 2005
- Employees
- 130
- Website
- diaxonhit.com ↗
Leadership
Pay as last reported
- Mr. Denis FortierChairman of the Board, Chief Executive Officer, since 2019€700,000
- Mr. Jean-Michel GrandmouginDeputy Chief Executive Officer, Director, since 2017€120,000
- Ms. Cathie MarsaisDeputy Chief Executive Officer€194,000
- Mr. Bosc OlivierDeputy Chief Executive Officer€243,000
- Mr. Herve Duchesne De LamotteDirector, since 2009€1.6m
- Mr. Gregoire SentilhesDirector - Represented by EurobioNext SAS
- Ms. Catherine CourboilletIndependent Director
- Mr. Patrick De RoquemaurelIndependent Director€30,000
- Mr. Michel PicotIndependent Director, since 2004€30,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eurobio Scientific SA possesses several strengths that contribute to its competitive advantage in the market. These include:
Weaknesses
- Despite its strengths, Eurobio Scientific SA also faces certain weaknesses that need to be addressed to maintain its competitive position:
Opportunities
- Eurobio Scientific SA can capitalize on several opportunities in the market to further enhance its growth and profitability:
Threats
- Eurobio Scientific SA faces certain threats that could impact its operations and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.